Kaigene Inks ~$378M Exclusive Licensing Agreement with Taisho Pharmaceutical for KG006 in Japan

Shots:Kaigene has entered into an exclusive licensing agreement with Taisho Pharmaceutical for the exclusive development & commercialization of KG006 in JapanAs per the deal, Taisho will acquire exclusive rights to develop & commercialise KG006 in Japan, with Kaigene receiving $5M upfront, up to $22M & ¥57.5B (~$351M) in development, regulatory & sales milestones,…

ByDipanshu Dixit11 hours ago

NEWS

Kaigene Inks ~$744M Licensing Deal with Celltrion for KG006 and KG002 to Treat Autoimmune Diseases

Shots:Kaigene has granted Celltrion exclusive global rights to develop & commercialize KG006 (excl. Greater China & Japan) & KG002As per the deal, Kaigene will receive $8M upfront, & ~$736M in milestone payments, incl. $11M in near-term milestones through the initiation of P-I trials, along with net sales-based tiered royaltiesKG006 is an FcRn…

ByRidhi RastogiNovember 4, 2025

Kaigene Inks ~$378M Exclusive Licensing Agreement with Taisho Pharmaceutical for KG006 in Japan

Kaigene Inks ~$744M Licensing Deal with Celltrion for KG006 and KG002 to Treat Autoimmune Diseases

Contact US

FOLLOW US